The Impact of Remote Ischemic Pre-Conditioning on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography and Angioplasty
A Double-Blind Randomized Clinical Trial
Keywords:
percutaneous coronary intervention, coronary angiography, kidney diseases, contrast-induced nephropathy, remote ischemic pre-conditioningAbstract
Background and objective: Contrast-induced nephropathy (CIN) is an acute major complication following intravascular administration of iodinated contrast agents; however, the best approach for preventing CIN is not clear. Remote ischemic pre-conditioning (RIPC) is a new, non-pharmacological method that has been considered for the prevention of CIN following coronary angiography. This study assessed the effects of RIPC with four brief episodes of upper limb ischemia and reperfusion in the prevention of contrast-induced nephropathy (CIN) after coronary angiography and/or angioplasty.
Methods: In this double-blind randomized clinical trial, we enrolled 51 patients with chronic stable angina and non-ST elevation acute coronary syndrome (NSTE.ACS), and they underwent coronary angiography and/or angioplasty. Standard fluid therapy with normal saline was prescribed for all patients before and after the procedure. The patients were divided into two groups, i.e., a study group of patients who had undergone RIPC intervention and a control group of patients who had not undergone RIPC. One hour before the procedure, a sphygmomanometer cuff was placed around one arm and inflated up to 50 mmHg above the systolic pressure for five minutes; then, the cuff was deflated for another five minutes, and this cycle was repeated four times. The patients’ serum creatinine levels were measured at baseline and 48 hours after the procedure, and the incidence of CIN was calculated.
Results: Twenty-one males and 30 females were studied in two groups, i.e., an RIPC intervention group (n = 25) and a control group (n = 26) that were homogenous considering baseline characteristics. No significant difference was observed in the mean level of serum creatinine between the two groups at a post-intervention time of 48 hours (RICP: 1.74 ± 0.70 mg/dL vs. Control: 1.75 ± 0.87 mg/dL; P = 0.64). However, a lower incidence rate of CIN was observed 48 hours after the administration of the contrast medium in the RIPC group, but it was not statistically significant (RIPC: 23.1% vs. Control: 12.0%; P = 0.30).
Conclusion: It seems that adequate fluid therapy is still the most effective strategy for preventing CIN and that RIPC might have additional protective effects in very high risk patients, such as those with severe renal insufficiency and heart failure.
Trial registration: The trial was registered at the Iranian Clinical Trial Registry (http://www.irct.ir) with the IRCT identification number IRCT2015061422713N1.
Funding: This research was supported financially by the Research Council of Mashhad University of Medical Sciences. The authors received no financial support for writing or publishing this article.
References
Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced
nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and
hemodynamic variables. Am J Cardiol. 2005; 95(1): 13-9. doi: 10.1016/j.amjcard.2004.08.056, PMID:
Aurelio A, Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis,
risk factors, outcome, prevention and treatment. Cardiology. 2014; 128(1): 62-72. doi: 10.1159/000358042,
PMID: 24557146.
Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European Renal Best Practice
(ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice
guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced
nephropathy. Nephrol Dial Transplant. 2012; 27(12): 4263–72. PMCID: PMC3520085.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction
of contrast-induced nephropathy after percutaneous coronary intervention: development and initial
validation. J Am Coll Cardiol .2004; 44(7): 1393-9. doi: 10.1016/j.jacc.2004.06.068.
Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med. 2001; 2
Suppl 1: S14-8. PMID: 12439363.
Bell RM, Rear R, Cunningham J, Dawnay A, Yellon DM. Effect of remote ischaemic conditioning on
contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale
and study design of a randomised single-centre, double-blind placebo-controlled trial. Clin Res Cardiol.
; 103(3): 203-9. doi: 10.1007/s00392-013-0637-3, PMID: 24292557. PMCID: PMC3937541.
Thomsen H, Morcos S. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR)
guidelines. Br J Radiol. 2014; 87(1042): 20140307. doi: 10.1259/bjr.20140307, PMID: 25230161, PMCID:
PMC4170864.
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced
nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21(12):2527- 41. doi: 10.1007/s00330-011-2225-0, PMID: 21866433.
Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote Ischemic Conditioning. J Am Coll
Cardiol. 2015; 65(2): 177-95. doi: 10.1016/j.jacc.2014.10.031, PMID: 25593060, PMCID: PMC4297315.
Seino Y. Remote Ischemic Conditioning. Circ J. 2013; 77(12): 2883-5. doi: 10.1253/circj.CJ-13-1297,
PMID: 24161905.
Igarashi G, Iino K, Watanabe H, Ito H. Remote ischemic pre-conditioning alleviates contrastinduced acute
kidney injury in patients with moderate chronic kidney disease. Circ J. 2013; 77(12): 3037-44. doi:
1253/circj.CJ-13-0171, PMID: 23986081.
Deftereos S, Giannopoulos G, Tzalamouras V, Raisakis K, Kossyvakis C, Kaoukis A, et al. Renoprotective
effect of remote ischemic post-conditioning by intermittent balloon inflations in patients undergoing
percutaneous coronary intervention. J Am Coll Cardiol. 2013; 61(19): 1949-55. doi:
1016/j.jacc.2013.02.023, PMID: 23500314.
Saxena P, Newman MA, Shehatha JS, Redington AN, Konstantinov IE. Remote ischemic conditioning:
evolution of the concept, mechanisms, and clinical application. J Card Surg. 2010; 25(1): 127-34. doi:
1111/j.1540-8191.2009.00820.x, PMID: 19549044.
Walsh SR, Boyle JR, Tang TY, Sadat U, Cooper DG, Lapsley M, et al. Remote ischemic preconditioning
for renal and cardiac protection during endovascular aneurysm repair: a randomized controlled trial. J
Endovasc Ther. 2009; 16(6): 680-9. doi: 10.1583/09-2817.1, PMID: 19995115.
Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, et al. Ischemic Preconditioning for
Prevention of Contrast Medium–Induced Nephropathy: Randomized Pilot RenPro Trial (Renal Protection
Trial). Circulation. 2012; 126(3): 296-303. doi: 10.1161/CIRCULATIONAHA.112.096370, PMID:
Turcot DB, Kiernan FJ, McKay RG, Grey NJ, Boden W, Perdrizet GA. Acute Hyperglycemia Implications
for contrast-induced nephropathy during cardiac catheterization. Diabetes care. 2004; 27(2): 620-1. doi:
2337/diacare.27.2.620, PMID: 14747256.
Freeman RV, O’Donnell M, Share D, Meengs WL, Kline-Rogers E, Clark VL, et al. Nephropathy requiring
dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J
Cardiol. 2002; 90(10): 1068-73. doi: 10.1016/S0002-9149(02)02771-6, PMID: 12423705.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.